David P. Langlois (DL 2319) SUTHERLAND ... - FDA Law Blog
David P. Langlois (DL 2319) SUTHERLAND ... - FDA Law Blog David P. Langlois (DL 2319) SUTHERLAND ... - FDA Law Blog
Case 1:09-cv-04665-DLC Document 49-2 Filed 03/30/2010 Page 10 of 451-42.COUNT II(INDUCEMENT OF INFRINGEMENT OF METHOD CLAIMS OF THE‘584 PATENT UNDER 35 U.S.C. § 271(b))43. Teva incorporates by reference as if stated fully herein its responses to Paragraphs44. Teva denies the allegations in Paragraph 44.45. Teva denies the allegations in Paragraph 45.46. Teva admits that the uses for which it seeks approval of ANDA No. 91-155 are setforth in the proposed labeling in that ANDA. Except as expressly admitted above, Teva denies theallegations in Paragraph 46.1-49.47. Teva denies the allegations in Paragraph 47.48. Teva denies the allegations in Paragraph 48.49. Teva denies the allegations in Paragraph 49.COUNT III(CONTRIBUTORY INFRINGEMENT OF THE ‘584 PATENTUNDER 35 U.S.C. § 271(c))50. Teva incorporates by reference as if stated fully herein its responses to Paragraphs51. Teva admits that the uses for which it seeks approval of ANDA No. 91-155 are setforth in the proposed labeling in that ANDA. Except as expressly admitted above, Teva denies theallegations in Paragraph 51.52. Teva denies the allegations in Paragraph 52.53. Teva denies the allegations in Paragraph 53.54. Teva denies the allegations in Paragraph 54.9067383.19
Case 1:09-cv-04665-DLC Document 49-2 Filed 03/30/2010 Page 11 of 451-54.COUNT IV(DIRECT INFRINGEMENT OF THE ‘043 PATENT UNDER35 U.S.C. § 271(e)(2)(A))55. Teva incorporates by reference as if stated fully herein its responses to Paragraphs56. Teva admits that Teva USA filed ANDA No. 91-155 with the FDA under 21 U.S.C.§ 355(j), seeking approval to market (i) combination Pioglitazone Hydrochloride and MetforminHydrochloride Tablets, Eq. to 15 mg base/500 mg, and (ii) combination PioglitazoneHydrochloride and Metformin Hydrochloride Tablets, Eq. to 15 mg base/850 mg. Except asexpressly admitted above, Teva denies the allegations in Paragraph 56.57. Upon information and belief, Teva USA admits that its combination pioglitazoneand metformin drug products will be AB rated to Takeda’s combination pioglitazone andmetformin drug products. Except as expressly admitted above, Teva denies the allegations inParagraph 57.58. Teva admits that Teva USA’s Notice Letter states that it submitted to the FDAANDA No. 91-155 “which seeks approval to engage in the commercial manufacture, use, or sale ofPioglitazone Hydrochloride and Metformin Hydrochloride, Eq. to 15 mg base/500 mg and Eq. to15 mg base/850 mg, prior to the expiration of the ‘584, ‘042, ‘043, and ‘090 patents.” Except asexpressly admitted above, Teva denies the allegations in Paragraph 58.59. Teva admits that, by a letter dated April 14, 2009, Teva USA informed Takeda thatTeva USA had filed a certification to the FDA, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV).Upon information and belief, Teva admits the remaining allegations in Paragraph 59.60. Teva admits that the Notice Letter provides Teva USA’s notification of certificationunder 21 U.S.C. § 355(j)(2)(B)(iv) and alleges, among other things, that in Teva USA’s opinion,9067383.110
- Page 1: Case 1:09-cv-04665-DLC Document 49-
- Page 5 and 6: Case 1:09-cv-04665-DLC Document 49-
- Page 8 and 9: Case 1:09-cv-04665-DLC Document 49-
- Page 12 and 13: Case 1:09-cv-04665-DLC Document 49-
- Page 14 and 15: Case 1:09-cv-04665-DLC Document 49-
- Page 16 and 17: Case 1:09-cv-04665-DLC Document 49-
- Page 18 and 19: Case 1:09-cv-04665-DLC Document 49-
- Page 20 and 21: Case 1:09-cv-04665-DLC Document 49-
- Page 22 and 23: Case 1:09-cv-04665-DLC Document 49-
- Page 24 and 25: Case 1:09-cv-04665-DLC Document 49-
- Page 26 and 27: Case 1:09-cv-04665-DLC Document 49-
- Page 28 and 29: Case 1:09-cv-04665-DLC Document 49-
- Page 30 and 31: Case 1:09-cv-04665-DLC Document 49-
- Page 32 and 33: Case 1:09-cv-04665-DLC Document 49-
- Page 34 and 35: Case 1:09-cv-04665-DLC Document 49-
- Page 36 and 37: Case 1:09-cv-04665-DLC Document 49-
- Page 38 and 39: Case 1:09-cv-04665-DLC Document 49-
- Page 40 and 41: Case 1:09-cv-04665-DLC Document 49-
- Page 42 and 43: Case 1:09-cv-04665-DLC Document 49-
- Page 44 and 45: Case 1:09-cv-04665-DLC Document 49-
Case 1:09-cv-04665-<strong>DL</strong>C Document 49-2 Filed 03/30/2010 Page 10 of 451-42.COUNT II(INDUCEMENT OF INFRINGEMENT OF METHOD CLAIMS OF THE‘584 PATENT UNDER 35 U.S.C. § 271(b))43. Teva incorporates by reference as if stated fully herein its responses to Paragraphs44. Teva denies the allegations in Paragraph 44.45. Teva denies the allegations in Paragraph 45.46. Teva admits that the uses for which it seeks approval of ANDA No. 91-155 are setforth in the proposed labeling in that ANDA. Except as expressly admitted above, Teva denies theallegations in Paragraph 46.1-49.47. Teva denies the allegations in Paragraph 47.48. Teva denies the allegations in Paragraph 48.49. Teva denies the allegations in Paragraph 49.COUNT III(CONTRIBUTORY INFRINGEMENT OF THE ‘584 PATENTUNDER 35 U.S.C. § 271(c))50. Teva incorporates by reference as if stated fully herein its responses to Paragraphs51. Teva admits that the uses for which it seeks approval of ANDA No. 91-155 are setforth in the proposed labeling in that ANDA. Except as expressly admitted above, Teva denies theallegations in Paragraph 51.52. Teva denies the allegations in Paragraph 52.53. Teva denies the allegations in Paragraph 53.54. Teva denies the allegations in Paragraph 54.9067383.19
Change language